Last reviewed 2026-08-25
The nootropic peptides are dominated by compounds registered in Russia and reviewed nowhere else, which leaves Western readers with a literature that is difficult to appraise independently. Dihexa warrants a specific warning: the 2014 paper establishing its proposed mechanism was retracted in April 2025, which removes the main published support for how it was said to work.
Semax and Selank were both developed in Russia and are registered medicines there, used for anxiety, cognition and stroke recovery. Neither has been reviewed by the FDA or the EMA.
This is not an argument that they do nothing. It is that the supporting literature is largely Russian-language, difficult to appraise against Western trial standards, and has not been independently replicated. That is a genuine limitation rather than a technicality.
Dihexa is a different and more serious case, and is covered here mainly so that the retraction is not something a reader discovers after buying it.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| Semax | Limited human data | Research | Not published |
| Selank | Limited human data | Research | Not published |
| Dihexa | No human evidence for this claim | Research | Not published |
ACTH fragment analogue used in Russia for cognitive and neuroprotective indications.
The catch: A registered medicine in Russia, unapproved in the US and EU. The evidence base has not been independently replicated to Western standards.
Tuftsin-derived anxiolytic peptide, usually taken as a nasal spray.
The catch: Same position as Semax: registered in Russia, unapproved and unreplicated elsewhere.
Angiotensin IV analogue studied preclinically for synapse formation.
The catch: The 2014 Journal of Pharmacology and Experimental Therapeutics paper establishing its HGF/c-Met mechanism was retracted in April 2025. It has never entered human trials.
Semax and Selank have the most clinical use behind them, entirely within the Russian medical system and without independent Western replication.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
Semax requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Semax is a registered medicine in Russia with clinical use behind it there, but it has not been approved or independently studied to Western trial standards. The evidence is real but difficult for an outside reader to appraise.
Its safety in humans is unknown, because it has never been through a human trial. The retraction in April 2025 of the paper establishing its proposed mechanism means even the animal-level rationale is now unsettled.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory